Robert E. Claypoole Sells 28,786 Shares of Bioventus Inc. (NYSE:BVS) Stock

Bioventus Inc. (NYSE:BVS) CEO Robert E. Claypoole sold 28,786 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total transaction of $261,952.60. Following the sale, the chief executive officer now directly owns 64,964 shares of the company’s stock, valued at approximately $591,172.40. This represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Bioventus Price Performance

BVS stock traded down $0.29 during trading on Tuesday, hitting $8.87. The company had a trading volume of 304,386 shares, compared to its average volume of 351,934. The company has a fifty day moving average price of $11.08 and a two-hundred day moving average price of $10.17. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The company has a market cap of $719.84 million, a P/E ratio of -14.54 and a beta of 0.85. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38.

Bioventus (NYSE:BVS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. The business had revenue of $138.96 million for the quarter, compared to analyst estimates of $132.57 million. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. During the same quarter in the previous year, the firm earned $0.05 EPS. Equities research analysts expect that Bioventus Inc. will post 0.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

BVS has been the subject of several recent analyst reports. Canaccord Genuity Group upped their price objective on shares of Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and upped their price objective for the company from $12.00 to $13.00 in a research report on Tuesday, December 17th. Finally, Craig Hallum raised their target price on Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, September 27th.

Institutional Trading of Bioventus

Several institutional investors have recently bought and sold shares of BVS. Charles Schwab Investment Management Inc. boosted its stake in Bioventus by 38.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock worth $4,662,000 after purchasing an additional 109,359 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Bioventus by 100.7% in the second quarter. Dimensional Fund Advisors LP now owns 117,496 shares of the company’s stock worth $676,000 after purchasing an additional 58,954 shares in the last quarter. Rhumbline Advisers boosted its stake in Bioventus by 5,367.9% in the second quarter. Rhumbline Advisers now owns 52,437 shares of the company’s stock worth $302,000 after purchasing an additional 51,478 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new position in Bioventus in the third quarter worth $4,515,000. Finally, Point72 Asset Management L.P. acquired a new position in Bioventus in the third quarter worth $788,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.